Sanofi SA ended the second quarter with sales of €10.7 billion, up by 7.8% from a year earlier and propelled by the continuing strong performance of Dupixent, the biologic co-developed with Regeneron Pharmaceuticals Inc. Dupixent generated €3.3 billion in the period, or nearly a third of group sales. Altogether, pharmaceutical products delivered €8.3 billion and vaccines, €1.14 billion. The company’s consumer business, which will be spun out in the fourth quarter, at the earliest, produced revenue of €.1.3 billion.
